ROR
RAR-related orphan receptor
Retinoic acid receptor-related orphan receptors (RORs) are a subfamily of the thyroid hormone receptor, which is a subfamily of the nuclear receptors and belonging to the orphan nuclear receptor family. The ROR subfamily contains three members: RORα (NR1F1), RORβ (NR1F2), and RORγ (NR1F3) and function as ligand-dependent transcription factors.
RORs are reported to activate transcription through ligand-dependent interactions with co-regulators and are involved in the development of secondary lymphoid tissues, autoimmune diseases, inflammatory diseases, the circadian rhythm, and metabolism homeostasis.
RORα and RORγ are important regulators of the immune system. The development and differentiation of Th17 cells are dependent on these factors. RORγ is expressed in lymphoid tissue inducer cells, innate lymphoid cells, invariant natural killer T cells, and γδ T cells, which contribute to inflammation and autoimmune disease.
ROR Isoform Specific Products
All Product Categories
-
ROR Inhibitors
(59)
View all products
-
ROR Agonists
(29)
View all products
-
ROR Antagonists
(37)
View all products
-
ROR Activators
(2)
View all products
-
ROR Modulators
(8)
View all products
-
ROR Inducer
(1)
View all products
-
ROR Degraders
(2)
View all products
-
ROR Control
(1)
View all products
-
ROR Ligands
(3)
View all products
-
ROR Related Products (148)
Related Products (148)
-
Antibodies (5)
-
ROR Isoform Comparison
-
RORγt agonist 1
0 ImagesCat. No.: HY-126321CAS No.: 2377378-89-5RORγt agonist 1 (compound 14) is a potent, orally bioavailable RORγt agonist with an EC50 of 20.8 nM. RORγt agonist 1 showes high metabolic stability, improved aqueous solubility and excellent mouse PK profile. RORγt agonist 1 is a potential candidate of RORγt agonist for cancer immunotherapy.
-
Retezorogant
0 ImagesCat. No.: HY-145590CAS No.: 1950570-48-5Retezorogant is a retinoid-related orphan receptor γ (RORγ) antagonist, extracted from patent WO2016093342 A1.
-
RORγ agonist 1
0 ImagesCat. No.: HY-132900CAS No.: 2260631-91-0RORγ agonist 1 is a potent and orally bioavailable RORγ agonist (EC50 = 21 nM) with antitumor activity.
-
RORγt inverse agonist 14
0 ImagesCat. No.: HY-132195CAS No.: 2672496-70-5RORγt inverse agonist 14 (8e) is a potent, orally active and selective RORγt inverse agonist (EC50 of 2.5 nM) with anti-inflammatory activity. RORγt inverse agonist 14 is used in the study for rheumatoid arthritis and psoriasis.
-
ROR agonist-1
0 ImagesCat. No.: HY-128353CAS No.: 2361528-74-5ROR agonist-1 is a potent and orally bioavailable inverse agonist of the retinoic acid receptor-related orphan receptor C2 (RORC2), inhibition of IL-17A production from human primary TH 17 cells with a pIC50 of 7.5.
-
RORγt Inverse agonist 2
0 ImagesCat. No.: HY-111748CAS No.: 1801197-92-1RORγt Inverse agonist 2 is a selective, orally active RORγt inverse agonist with an EC50 of 119 nM.
-
FM26
0 ImagesCat. No.: HY-133128CAS No.: 2407981-35-3FM26 (compound 25) is a potent and allosteric retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists with an IC50 of 264 nM. FM26 has a distinct isoxazole chemotype and effectively reduces IL-17a mRNA production in EL4 cells.
-
RORγt inverse agonist 26
0 ImagesCat. No.: HY-142806CAS No.: 2738333-10-1RORγt inverse agonist 26 is a potent reverse agonist of RORγt. RORγt inverse agonist 26 regulates the differentiation of Th17 cells and inhibits the production of IL-17. RORγt inverse agonist 26 has the potential for the research of inflammation and autoimmune diseases (extracted from patent WO2021228215A1, compound 1) .
-
TAK-828F
0 ImagesCat. No.: HY-111509CAS No.: 1854901-94-2TAK-828F is a potent, selective, and orally available retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist (binding IC50=1.9 nM, reporter gene IC50=6.1 nM). TAK-828F shows excellent RORγt isoforms selectivity (>5000-fold selectivity against human RORα and RORβ).
-
A-9758
0 ImagesCat. No.: HY-126252CAS No.: 2055271-22-0A-9758 is a RORγ ligand and a potent, selective RORγt inverse agonist (IC50=5 nM), and exhibits robust potency against IL-17A release. A-9758 is effective in suppressing both Th17 differentiation and Th17 effector function. A-9758 significantly attenuates IL-23 driven psoriasiform dermatitis and is effective in blocking skin and joint inflammation.
-
ARN-6039
0 ImagesCat. No.: HY-115777CAS No.: 1675206-11-7ARN-6039 is an orally available inverse agonist of RORγ for autoimmune demyelinating disease.
-
SHR168442
0 ImagesCat. No.: HY-115879CAS No.: 2382961-86-4SHR168442 is a modulator of retinoid-related orphan receptor gamma (RORγ) with an IC50 value of 0.035 μM.
-
RORγt Inverse agonist 8
0 ImagesCat. No.: HY-122737CAS No.: 2079892-79-6RORγt Inverse agonist 8 is a potent, selective, orally bioavailable RORγt inverse agonist, with an IC50 of 19 nM for human RORγt-LBD.
-
RORγt inverse agonist 35
0 ImagesCat. No.: HY-176273RORγt inverse agonist 35 (Compound 22) is a RORγt inverse agonist with an IC50 of 1.51 μM. RORγt inverse agonist 35 significantly inhibits Th17 differentiation and proinflammatory properties in human CD4+ T cells. RORγt inverse agonist 35 can be used for research of Th17-driven autoimmune diseases, such as psoriasis, multiple sclerosis, and inflammatory bowel disease (IBD).
-
RORγt modulator 5
0 ImagesCat. No.: HY-142940CAS No.: 2119042-65-6RORγt modulator 5 is a RORγt modulator with a Ki value of <100 nM. RORγt modulator 5 has the potential for inflammatory, metabolic, autoimmune and other diseases mediated by RORy study (WO2017132432A1; compound 2).
-
RORγ antagonist 1
0 ImagesCat. No.: HY-155542CAS No.: 3049676-15-2RORγ antagonist 1 (compound 22), a potent betulinic acid derivative, is an antagonist of RORγ (KD=0.18 μM). RORγ antagonist 1 exhibits anti-proliferative activity in HPAF-II pancreatic cancer xenograft model. RORγ antagonist 1 inhibits RAS/MAPK and AKT/mTORC1 pathway, and induces caspase-dependent apoptosis in pancreatic cancer cells.
-
3-Oxo-5β-cholanoic acid-d4
0 ImagesCat. No.: HY-125801SSynonyms: Dehydrolithocholic acid-d4; 3-oxoLCA-d43-Oxo-5β-cholanoic acid-d4 (Dehydrolithocholic acid-d4) is the deuterium labeled 3-Oxo-5β-cholanoic acid (HY-125801). 3-Oxo-5β-cholanoic acid (Dehydrolithocholic acid), a bile acid metabolite, inhibits the diferentiation of TH17 cells by directly binding to the key transcription factor RORγt (Kd=1.13 μM).
-
RORA Human Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS12126RORA Human Pre-designed siRNA Set A contains three designed siRNAs for RORA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
